BioNTech (NASDAQ:BNTX) Shares Gap Down - What's Next?

Key Points

• BioNTech shares gapped down — the stock opened at $98.48 after a $103.45 close and last traded around $97.26 on volume ~152,889, trading just below its 50‑day ($97.52) and under its 200‑day ($101.14) moving averages.
• Analyst sentiment is mixed but leaning positive — MarketBeat shows an average rating of "Moderate Buy" with an average target of $133.13 (1 Strong Buy, 12 Buy, 4 Hold, 1 Sell), while firms have recently both upgraded and downgraded the stock.
• Insider selling noted — COO Sierk Poetting sold 50,000 shares at an average $110.56 under a 10b5‑1 plan, though insiders still own about 19.2% of the company.

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $103.45, but opened at $98.48. BioNTech shares last traded at $97.2550, with a volume of 152,889 shares changing hands.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on BNTX. Leerink Partners lowered shares of BioNTech from an "outperform" rating to a "market perform" rating and set a $113.00 price target on the stock. in a research report on Monday, February 2nd. Truist Financial upgraded shares of BioNTech to a "strong-buy" rating in a research report on Wednesday, March 25th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of BioNTech in a research report on Tuesday, March 17th. Citigroup lowered their price target on shares of BioNTech from $145.00 to $130.00 and set a "buy" rating on the stock in a research report on Wednesday, March 11th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of BioNTech in a research report on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $133.13.

BioNTech Price Performance

The stock has a market capitalization of $24.70 billion, a PE ratio of -18.65 and a beta of 1.58. The company has a current ratio of 7.54, a quick ratio of 7.49 and a debt-to-equity ratio of 0.01. The company's 50 day simple moving average is $97.52 and its 200 day simple moving average is $101.14.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The firm had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 4.76% and a negative net margin of 38.09%. On average, equities analysts anticipate that BioNTech SE Sponsored ADR will post -4.55 earnings per share for the current year.

Insider Buying and Selling

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer directly owned 399,387 shares of the company's stock, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company's stock.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently bought and sold shares of BNTX. Larson Financial Group LLC raised its stake in BioNTech by 86.4% during the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company's stock worth $26,000 after purchasing an additional 127 shares during the period. EFG International AG purchased a new position in BioNTech during the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd raised its stake in BioNTech by 520.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company's stock worth $30,000 after purchasing an additional 260 shares during the period. Financial Consulate Inc. purchased a new position in BioNTech during the third quarter worth approximately $36,000. Finally, Huntington National Bank raised its stake in BioNTech by 1,266.7% during the third quarter. Huntington National Bank now owns 410 shares of the company's stock worth $40,000 after purchasing an additional 380 shares during the period. Hedge funds and other institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE NASDAQ: BNTX is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech's core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.